CONGRESS|#EHA2021| Jason Valent, Taussig Cancer Institute presented study on safety & tolerability through 4 weeks of treatment with CAEL-101+CyBorD & CAEL-101+CyBorD+daratumumab in amyloidosis pts. 1000mg/sq.m was well-tolerated. #mmsm,#myeloma pic.twitter.com/MysG1m3AnC
— Multiple Myeloma Hub (@MM_Hub) June 14, 2021